An interventional study of Progressive Walking Exercise Programme and Real-time air quality information and guidance in Cardiovascular Disease, Asthma and COPD, sponsored by University of Leicester. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Leicester · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) programmes via an online platform that delivers both exercise prescription and air pollution guidance. Specific objectives are: (1) to determine whether access to real-time air quality data reduces modelled ambient pollution exposure (PM2.5, PM10 and NO2) during outdoor physical activity in CR/PR patients and healthy volunteers; (2) to assess the feasibility of the trial design, including recruitment, randomisation, retention, adherence and completeness of outcome data; (3) to measure the impact of the intervention on physical activity levels, health-related quality of life and cardiovascular biomarkers; and (4) to inform the design and sample size of a future definitive randomised controlled trial
EPIC-AIR is a single-site, stratified, blinded, two-arm randomised controlled feasibility trial conducted at University Hospitals of Leicester NHS Trust. Up to 80 participants comprising cardiac rehabilitation patients, pulmonary rehabilitation patients and healthy volunteers will be recruited. Following a 1-week baseline monitoring period, participants will be stratified by participant group (cardiac rehabilitation, pulmonary rehabilitation or healthy volunteer) and randomised 1:1 within strata using a computer-generated allocation sequence via the Sealed Envelope secure web-based system.
All participants will receive a Fitbit Charge 6 and a 12-week progressive walking programme delivered through the P-STEP platform. Participants allocated to the intervention arm will additionally receive real-time local PM2.5, PM10 and NO2 information and adaptive guidance concerning the timing, location, route or intensity of outdoor activity. Participants in the control arm will use the same platform and receive the same exercise guidance but without air-quality information or pollution-related guidance.
The primary outcomes are three co-primary pollutant-specific measures: weekly time-weighted mean modelled ambient PM2.5, PM10 and NO2 concentrations during moderate-to-vigorous physical activity (MVPA). Time-stamped GPS locations recorded during activity will be linked to wearable-derived activity data and contemporaneous modelled air-quality concentrations. These outcomes represent modelled ambient concentrations encountered during recorded activity rather than directly measured personal inhaled dose.
Weekly pollution exposure during the 12-week intervention will be analysed using repeated-measures mixed-effects models accounting for participant clustering, baseline exposure, study week, randomisation stratum, sex and calendar week. The principal treatment contrast will be the adjusted average intervention-control difference across the 12-week post-allocation period. Multiplicity across the three co-primary pollutants will be controlled using the Holm procedure.
The registered secondary outcome is weekly physical activity derived from wrist-worn accelerometry. Additional clinical, physiological and patient-reported outcomes will be explored. Feasibility outcomes include recruitment, retention, adherence, completeness of outcome data and adverse events. A final follow-up assessment will take place 3 months after completion of the 12-week intervention. No participants had been recruited at the time the registry record was revised.
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 80 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the 12-week progressive walking programme through the P-STEP platform together with real-time PM2.5, PM10 and NO2 information and adaptive pollution-related guidance concerning exercise route, timing and/or intensity.
Other: Progressive Walking Exercise Programme · Behavioral: Real-time air quality information and guidance
Participants receive the same 12-week progressive walking programme through the P-STEP platform, with the same exercise guidance and tracking functions, but without air-quality information or pollution-related guidance.
Other: Progressive Walking Exercise Programme
Participants will receive a progressive, personalised walking exercise programme aimed to increase their weekly levels of physical activity over a 12 week study period.
Real-time air quality information and guidance provided by the online platform.
Weekly time-weighted mean modelled ambient PM2.5 concentration during moderate-to-vigorous physical activity
Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient PM2.5 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient PM2.5 concentration for each participant.
Time frame: 1-week baseline and weekly throughout the 12 week intervention
Weekly time-weighted mean modelled ambient PM10 concentration during moderate-to-vigorous physical activity
Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient PM10 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient PM10 concentration for each participant.
Time frame: 1-week baseline and weekly throughout the 12 week intervention
Weekly time-weighted mean modelled ambient NO2 concentration during moderate-to-vigorous physical activity
Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient NO2 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient NO2 concentration for each participant.
Time frame: 1-week baseline and weekly throughout the 12 week intervention
Weekly physical activity (weekly minutes, measured by wrist-worn accelerometry)
Mean minutes of moderate to vigorous physical activity measured continuously over the 12-week intervention period using a wrist-worn accelerometer. The comparison will be change from baseline in mean weekly minutes between the air quality information and control arms at 12 weeks.
Time frame: 1-week baseline and weekly throughout the 12-week intervention
Plan to share: No — Individual participant data will not be shared owing to the sensitive nature of the data collected, which includes continuous GPS-linked location tracking and personal physical activity monitoring. Sharing of granular location data at the individual level would risk re-identification of participants despite anonymisation. Aggregate summary data and analysis code will be made available upon reasonable request to the corresponding author following publication.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 5 months is below that.
Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start May 2026 → Oct 2026, primary completion Dec 2026 → Mar 2027 and completion Mar 2027 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.